E-ISSN 2534-9821
 
2023, Vol: 7, Issue: 11
7 / 11Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Transfer Form

Review Article
Online Published: 30 Sep 2019
 


Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC)

John Nolan, Agatha Nadya Lianto, Audrey Rachel Wijaya, Cokorda Agung Wahyu Purnamasidhi.


Abstract
Sepsis-induced coagulopathy (SIC) is a unique and urgent condition characterized by coagulation activation, overexpression of fibrinolysis, and high risk of organ dysfunction following sepsis. SIC is one of the complications of sepsis that is leading to high mortality rate. Due to the fact that there is no exact effective therapeutic agents specifically designed for SIC, new modalities are needed regarding the potential effect to suppress the mortality rate. Antithrombin (AT) and recombinant thrombomodulin (rhTM) are drugs which can promote anticoagulant activity. These natural anticoagulants work complementary to each other so that may suppress damage-associated molecular patterns (DAMPs) which is a process that may trigger endogenous molecule worsening the SIC. AT and rhTM have similar clinical effect on the other hand this AT-rhTM combination works on different sites and targets in the process. AT-rhTM combination may also suppress leukocyte adhesion and the elevation of circulating levels of nucleosome which leading to cell death event. Unfortunately, AT-rhTM combination costs extremely expensive. This article is done by searching journals with keywords “antithrombin”, “thrombomodulin”, and “sepsis induced coagulopathy” on the search engines. From 55 journals that were reviewed, 46 were found suitable as reference for this paper. AT-rhTM agent on SIC may reduce the mortality rate following some mechanisms. Further researches are required to identify the efficacy and effectivity of the AT-rhTM combination in treating patients with SIC

Key words: AT-rhTM combination, mortality, SIC


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by John Nolan
Articles by Agatha Nadya Lianto
Articles by Audrey Rachel Wijaya
Articles by Cokorda Agung Wahyu Purnamasidhi
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Nolan J, Lianto AN, Wijaya AR, Purnamasidhi CAW, . Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC). Int J Med Rev Case Rep. 2019; 3(11): 724-729. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin

Web Style

Nolan J, Lianto AN, Wijaya AR, Purnamasidhi CAW, . Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC). https://www.mdpub.net/?mno=58353 [Access: October 13, 2024]. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin

AMA (American Medical Association) Style

Nolan J, Lianto AN, Wijaya AR, Purnamasidhi CAW, . Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC). Int J Med Rev Case Rep. 2019; 3(11): 724-729. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin


Vancouver/ICMJE Style

Nolan J, Lianto AN, Wijaya AR, Purnamasidhi CAW, . Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC). Int J Med Rev Case Rep. (2019), [cited October 13, 2024]; 3(11): 724-729. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin


Harvard Style

Nolan, J., Lianto, A. N., Wijaya, A. R., Purnamasidhi, C. A. W. & (2019) Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC). Int J Med Rev Case Rep, 3 (11), 724-729. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin


Turabian Style

Nolan, John, Agatha Nadya Lianto, Audrey Rachel Wijaya, Cokorda Agung Wahyu Purnamasidhi, and . 2019. Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC). International Journal of Medical Reviews and Case Reports, 3 (11), 724-729. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin


Chicago Style

Nolan, John, Agatha Nadya Lianto, Audrey Rachel Wijaya, Cokorda Agung Wahyu Purnamasidhi, and . "Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC)." International Journal of Medical Reviews and Case Reports 3 (2019), 724-729. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin


MLA (The Modern Language Association) Style

Nolan, John, Agatha Nadya Lianto, Audrey Rachel Wijaya, Cokorda Agung Wahyu Purnamasidhi, and . "Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC)." International Journal of Medical Reviews and Case Reports 3.11 (2019), 724-729. Print. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin


APA (American Psychological Association) Style

Nolan, J., Lianto, A. N., Wijaya, A. R., Purnamasidhi, C. A. W. & (2019) Antithrombin (AT) and Recombinant Human Thrombomodulin (rhTM) Combination as New Therapeutic Breakthrough in Managing Sepsis-Induced Coagulopathy (SIC). International Journal of Medical Reviews and Case Reports, 3 (11), 724-729. doi:10.5455/IJMRCR.Antithrombin-and-Recombinant-Human-Thrombomodulin


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports  (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500